Table 2.
Distribution frequency of CD44 genotypes of patients with lung adenocarcinoma and multiple logistic regression analysis of EGFR mutation association.
| All Cases (N = 279) | ||||
|---|---|---|---|---|
| SNP Genotypes | Wild Type (N = 110) | Mutation Type (N = 169) | AOR (95% CI) | p Value |
| rs1425802 | ||||
| AA | 38 (34.5%) | 64 (37.9%) | 1.00 | |
| AG | 51 (46.4%) | 77 (45.6%) | 0.867 (0.499–1.507) | p = 0.613 |
| GG | 21 (19.1%) | 28 (16.6%) | 0.710 (0.345–1.462) | p = 0.353 |
| AG + GG | 72 (65.5%) | 105 (62.1%) | 0.821 (0.489–1.380) | p = 0.457 |
| rs187115 | ||||
| AA | 74 (67.3%) | 118 (69.8%) | 1.00 | |
| AG | 33 (30.0%) | 45 (26.6%) | 0.846 (0.487–1.469) | p = 0.552 |
| GG | 3 (2.7%) | 6 (3.6%) | 1.438 (0.335–6.170) | p = 0.625 |
| AG + GG | 36 (32.7%) | 51 (30.2%) | 0.893 (0.524–1.520) | p = 0.676 |
| rs713330 | ||||
| TT | 94 (85.5%) | 147 (87.0%) | 1.00 | |
| TC | 15 (13.6%) | 21 (12.4%) | 1.052 (0.502–2.207) | p = 0.893 |
| CC | 1 (0.9%) | 1 (0.6%) | 0.643 (0.036–11.491) | p = 0.764 |
| TC + CC | 16 (14.5%) | 22 (13.0%) | 1.024 (0.498–2.106) | p = 0.949 |
| rs11821102 | ||||
| GG | 98 (89.1%) | 149 (88.2%) | 1.00 | |
| GA | 11 (10.0%) | 17 (10.1%) | 0.905 (0.396–2.070) | p = 0.813 |
| AA | 1 (0.9%) | 3 (1.7%) | 2.076 (0.199–21.675) | p = 0.542 |
| GA + AA | 12 (10.9%) | 20 (11.8%) | 0.995 (0.453–2.185) | p = 0.989 |
| rs10836347 | ||||
| CC | 96 (87.3%) | 141 (83.4%) | 1.00 | |
| CT | 14 (12.7%) | 27 (16.0%) | 1.275 (0.623–2.607) | p = 0.506 |
| TT | 0 (0%) | 1 (0.6%) | ---- | --- |
| CT + TT | 14 (12.7%) | 28 (16.6%) | 1.311 (0.643–2.673) | p = 0.456 |
| rs13347 | ||||
| CC | 47 (42.7%) | 76 (45.0%) | 1.00 | |
| CT | 57 (51.8%) | 79 (46.7%) | 0.958 (0.571–1.609) | p = 0.873 |
| TT | 6 (5.5%) | 14 (8.3%) | 1.657 (0.578–4.749) | p = 0.348 |
| CT + TT | 63 (57.3%) | 93 (55.0%) | 1.025 (0.619–1.696) | p = 0.924 |
The adjusted odds ratios (AORs) with 95% confidence intervals (Cis) were estimated by multiple logistic regression models after controlling for age and gender. Abbreviations: SNP, single nucleotide polymorphism; AOR, adjusted odds ratio; CI, confidence interval.